Clinical Cancer Research · 2018 · 77 citations · 35 references
MedicineCell BiologyOncologyMolecular OncologyStem Cell BiologyTumor MicroenvironmentAndrogen Deprivation TherapyCancer ProgressionCancer Stem Cell BiologyCancer Stem Cell MaintenanceCancer Stem Cell NicheCancer Stem CellsAndrogen Deprivation Therapy ResistanceCancer Stem Cell - Mediated ResistanceCancer Stem Cell Niche InteractionsCancer Stem Cell NichesCancer Stem Cell TargetingCancer Stem-like CellsCancer-associated MacrophagesTumor-associated Macrophage Interactions
Abstract Purpose: Cancer stem-like cells (CSC) contribute to the progression and androgen deprivation therapy (ADT) resistance of prostate cancer. As CSCs depend on their specific niche, including tumor-associated macrophages (TAM), elucidating the network between CSCs and TAMs may help to effectively inhibit the progression and ADT resistance of prostate cancer. Experimental Design: The underlying intracellular mechanism that sustains the stem-like characteristics of CSCs in prostate cancer was assessed via RNA sequencing, co-immunoprecipitation, chromatin immunoprecipitation, and other assays. A coculture system and cytokine antibody arrays were used to examine the interaction network between CSCs and TAMs. In addition, an orthotopic prostate cancer model was established to evaluate the in vivo effects of the combined targeting of CSCs and their interaction with TAMs on ADT resistance. Results: Autophagy-related gene 7 (ATG7) facilitated the transcription of OCT4 via β-catenin, which binds to the OCT4 promoter, promoting CSC characteristics in prostate cancer, including self-renewal, tumor initiation, and drug resistance. In addition, CSCs remodeled their specific niche by educating monocytes/macrophages toward TAMs, and the CSC-educated TAMs reciprocally promoted the stem-like properties of CSCs, progression and ADT resistance of prostate cancer via IL6/STAT3. Furthermore, the combined targeting of CSCs and their interaction with TAMs by inhibiting ATG7/OCT4 and IL6 receptor effectively ameliorated ADT resistance in an orthotopic prostate cancer model. Conclusions: Targeting CSCs and their niche may prove to be a more powerful strategy than targeting CSCs alone, providing a rational approach to ameliorating ADT resistance in prostate cancer. Clin Cancer Res; 24(18); 4612–26. ©2018 AACR.
35
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2018 · 17K citations · Full text
Senescence-associated reprogramming promotes cancer stemness
Maja Milanovic, Dorothy Ngo-Yin Fan, Dimitri Belenki et al. · Nature · 2017 · 1.1K citations
Medicine, Cancer Biology, Oncology +12
Wnt Signaling through Inhibition of β-Catenin Degradation in an Intact Axin1 Complex
Vivian Li, Ser Sue Ng, Paul J. Boersema et al. · Cell · 2012 · 903 citations · Full text